EPIMAC SIGNED
The next generation epigenetic medicine for inflammation
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0EPIMAC project word cloud
Explore the words cloud of the EPIMAC project. It provides you a very rough idea of what is the project "EPIMAC" about.
Project "EPIMAC" data sheet
The following table provides information about the project.
| Coordinator |
AMC MEDICAL RESEARCH BV
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Project website | http://www.epimac.eu/ |
| Total cost | 1˙294˙785 € |
| EC max contribution | 1˙294˙785 € (100%) |
| Programme |
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers) |
| Code Call | H2020-MSCA-ITN-2014 |
| Funding Scheme | MSCA-ITN-EID |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-01-01 to 2019-06-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | AMC MEDICAL RESEARCH BV | NL (AMSTERDAM ZUIDOOST) | coordinator | 1˙021˙497.00 |
| 2 | GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. | UK (BRENTFORD) | participant | 273˙287.00 |
| 3 | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM | NL (AMSTERDAM) | participant | 0.00 |
| 4 | Eureka | NL (Mechelen) | partner | 0.00 |
| 5 | UNIVERSITAIR MEDISCH CENTRUM UTRECHT | NL (UTRECHT) | partner | 0.00 |
Map
Project objective
Epigenetic mechanisms allow cells to adjust gene expression in response to environmental cues. Increased understanding of this area has led to excitement about the potential of applying epigenetic regulation to drug discovery. EPIMAC aims to pursue the potential of epigenetics as a novel and innovative therapeutic modality for immuno-inflammatory diseases, in particular Inflammatory Bowel Disease (IBD). IBD is a severe and disabling chronic inflammation of the gastrointestinal tract affecting millions of people worldwide. Current treatment strategies are not successful because the precise etiology unclear. It is increasingly clear that deregulated epigenetic processes are associated with the aberrant inflammatory response seen in IBD. Recent reports suggest that inhibitors of epigenetic modifications developed by GlaxoSmithKline (GSK), such as histone deacetylase (HDAC) inhibitors, bear potential in treating inflammatory states (Nicodeme et al, Nature 2010; Kruidenier et al, Nature 2012). The EPIMAC consortium has the ambition to educate a group of next-generation scientists that master genetics, epigenetics, target discovery, pharmacology, preclinical validation and regulatory issues, and at the same time have a good understanding of clinical implementations of the drug pipeline of our pharmaceutical partner GSK. GSK is one of the world's leading research-based pharmaceutical and healthcare companies that aims to team up with academic partners in EPIMAC through its dedicated discovery performance unit named EpiNova in conjunction with 2 immuno-pharmacology units. An SME specializing in epigenetic compound targeting to inflammatory cells, Chroma Therapeutics, will contribute technology to EPIMAC. EPIMAC will educate and train these scientists by providing them with a versatile and multidisciplinary doctoral program, allowing them to become excellent scientists skilled to overcome the current challenges in IBD.
Deliverables
| Management, administration and finance 5d | Documents, reports | 2020-01-14 14:21:31 |
| Research dissemination | Other | 2020-01-14 14:21:31 |
| Management, administration and finance 5c | Documents, reports | 2019-07-10 15:36:56 |
Take a look to the deliverables list in detail: detailed list of EPIMAC deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Andrew Y. F. Li Yim, Jessica R. de Bruyn, Nicolette W. Duijvis, Catriona Sharp, Enrico Ferrero, Wouter J. de Jonge, Manon E. Wildenberg, Marcel M. A. M. Mannens, Christianne J. Buskens, Geert R. D’Haens, Peter Henneman, Anje A. te Velde A distinct epigenetic profile distinguishes stenotic from non-inflamed fibroblasts in the ileal mucosa of Crohn’s disease patients published pages: e0209656, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0209656 |
PLOS ONE 13/12 | 2019-07-10 |
| 2018 |
Annette E. Neele, Marion J.J. Gijbels, Saskia van der Velden, Marten A. Hoeksema, Marieke C.S. Boshuizen, Koen H.M. Prange, Hung-Jen Chen, Jan Van den Bossche, Cindy P.P.A. van Roomen, Annelie Shami, Johannes H.M. Levels, Jeffrey Kroon, Tina Lucas, Stefanie Dimmeler, Esther Lutgens, Menno P.J. de Winther Myeloid Kdm6b deficiency results in advanced atherosclerosis published pages: 156-165, ISSN: 0021-9150, DOI: 10.1016/j.atherosclerosis.2018.05.052 |
Atherosclerosis 275 | 2019-07-10 |
| 2016 |
Jan Van den Bossche, Jeroen Baardman, Natasja A. Otto, Saskia van der Velden, Annette E. Neele, Susan M. van den Berg, Rosario Luque-Martin, Hung-Jen Chen, Marieke C.S. Boshuizen, Mohamed Ahmed, Marten A. Hoeksema, Alex F. de Vos, Menno P.J. de Winther Mitochondrial Dysfunction Prevents Repolarization of Inflammatory Macrophages published pages: 684-696, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2016.09.008 |
Cell Reports 17/3 | 2019-07-10 |
| 2016 |
Andrew Y. F. Li Yim, Nicolette W. Duijvis, Jing Zhao, Wouter J. de Jonge, Geert R. A. M. D’Haens, Marcel M. A. M. Mannens, Adri N. P. M. Mul, Anje A. te Velde, Peter Henneman Peripheral blood methylation profiling of female Crohn’s disease patients published pages: , ISSN: 1868-7075, DOI: 10.1186/s13148-016-0230-5 |
Clinical Epigenetics 8/1 | 2019-07-10 |
| 2017 |
Vincent A. van der Mark, Mohammed Ghiboub, Casper Marsman, Jing Zhao, Remco van Dijk, Johan K. Hiralall, Kam S. Ho-Mok, Zoë Castricum, Wouter J. de Jonge, Ronald P. J. Oude Elferink, Coen C. Paulusma Phospholipid flippases attenuate LPS-induced TLR4 signaling by mediating endocytic retrieval of Toll-like receptor 4 published pages: 715-730, ISSN: 1420-682X, DOI: 10.1007/s00018-016-2360-5 |
Cellular and Molecular Life Sciences 74/4 | 2019-07-10 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIMAC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EPIMAC" are provided by the European Opendata Portal: CORDIS opendata.
